Acute Lung Injury - Pipeline Review, H2 2015

Date: December 23, 2015
Pages: 105
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AD39C797CC5EN
Leaflet:

Download PDF Leaflet

Acute Lung Injury - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Acute Lung Injury - Pipeline Review, H2 2015’, provides an overview of the Acute Lung Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Lung Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Lung Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acute Lung Injury Overview
Therapeutics Development
Pipeline Products for Acute Lung Injury - Overview
Pipeline Products for Acute Lung Injury - Comparative Analysis
Acute Lung Injury - Therapeutics under Development by Companies
Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes
Acute Lung Injury - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Acute Lung Injury - Products under Development by Companies
Acute Lung Injury - Products under Investigation by Universities/Institutes
Acute Lung Injury - Companies Involved in Therapeutics Development
Altor BioScience Corporation
Apeptico Forschung und Entwicklung GmbH
Bayer AG
BioMarck Pharmaceuticals, Ltd.
Carolus Therapeutics, Inc.
CompleGen, Inc.
FirstString Research, Inc.
GlaxoSmithKline Plc
Histocell S.L.
Navigen Pharmaceuticals, Inc.
Noxxon Pharma AG
Quark Pharmaceuticals, Inc.
S-Evans Biosciences, Inc.
Silence Therapeutics Plc
Stemedica Cell Technologies, Inc.
Xiber Science GmbH
Acute Lung Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALT-836 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atu-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atu-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-858501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-10901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CGX-1037 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT-2009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HC-016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LTI-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAV-2729 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOXD-19 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P- BEFizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPLI-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1229 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solnatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Acute Lung Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stromal Cell Therapy for Acute Lung Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXA-302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xib-1301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Lung Injury - Recent Pipeline Updates
Acute Lung Injury - Dormant Projects
Acute Lung Injury - Discontinued Products
Acute Lung Injury - Product Development Milestones
Featured News & Press Releases
Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis
Sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics
Jan 20, 2012: Carolus Therapeutics Reports Publication Of Preclinical Data For CT-2009 Supporting Development In Acute Lung Injury
Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Lung Injury, H2 2015
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Acute Lung Injury - Pipeline by Altor BioScience Corporation, H2 2015
Acute Lung Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2015
Acute Lung Injury - Pipeline by Bayer AG, H2 2015
Acute Lung Injury - Pipeline by BioMarck Pharmaceuticals, Ltd., H2 2015
Acute Lung Injury - Pipeline by Carolus Therapeutics, Inc., H2 2015
Acute Lung Injury - Pipeline by CompleGen, Inc., H2 2015
Acute Lung Injury - Pipeline by FirstString Research, Inc., H2 2015
Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H2 2015
Acute Lung Injury - Pipeline by Histocell S.L., H2 2015
Acute Lung Injury - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015
Acute Lung Injury - Pipeline by Noxxon Pharma AG, H2 2015
Acute Lung Injury - Pipeline by Quark Pharmaceuticals, Inc., H2 2015
Acute Lung Injury - Pipeline by S-Evans Biosciences, Inc., H2 2015
Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H2 2015
Acute Lung Injury - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
Acute Lung Injury - Pipeline by Xiber Science GmbH, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Acute Lung Injury Therapeutics - Recent Pipeline Updates, H2 2015
Acute Lung Injury - Dormant Projects, H2 2015
Acute Lung Injury - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Acute Lung Injury, H2 2015
Number of Products under Development for Acute Lung Injury - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Altor BioScience Corporation
Apeptico Forschung und Entwicklung GmbH
Bayer AG
BioMarck Pharmaceuticals, Ltd.
Carolus Therapeutics, Inc.
CompleGen, Inc.
FirstString Research, Inc.
GlaxoSmithKline Plc
Histocell S.L.
Navigen Pharmaceuticals, Inc.
Noxxon Pharma AG
Quark Pharmaceuticals, Inc.
S-Evans Biosciences, Inc.
Silence Therapeutics Plc
Stemedica Cell Technologies, Inc.
Xiber Science GmbH
Skip to top


Ask Your Question

Acute Lung Injury - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: